Teva nears deal for Allergan's generic drugs unit: source
By Greg Roumeliotis
(Reuters) - Teva Pharmaceutical Industries Ltd (TEVA.TA: Quote) is in advanced talks to buy Allergan Plc's (AGN.N: Quote) generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV (MYL.O: Quote), according to a person familiar with the matter.
Jerusalem-based Teva, which has offered to buy Mylan for $40 billion, is now close to an agreement to acquire Dublin-based Allergan's generic drugs unit for between $40 billion and $45 billion, the person said on Saturday.
A deal could be announced as early as next week, the person said, cautioning that negotiations had not yet been completed and asking not to be identified because the discussions are confidential. Teva and Allergan representatives did not respond to requests for comment.
Large drug makers are trying to realign their operations to focus on a small number of leading businesses, while smaller specialty and generic producers are seeking larger scale. Allergan's branded drugs business makes products such as Botox and Alzheimer's drug Namenda. Its generics business makes up about a third of the company's total revenue.
A successful deal with Allergan would give Teva, which has a market capitalization of $60 billion, a much bigger footprint in the generic drugs sector. It would also offer opportunities for significant cost synergies and tax savings.
Last year, Actavis Plc outbid Canadian drugmaker Valeant Pharmaceuticals International Inc (VRX.TO: Quote) and activist investor William Ackman to merge with Allergan and adopt its name. Allergan now has a market capitalization of $121 billion.
Teva's bid for Mylan took a hit earlier this week when the latter's independent Dutch foundation exercised a call option allowing it to buy 50 percent of Mylan's total issued and outstanding capital, giving it temporary control of half the company.
The foundation, known as Stichting, opposes Teva's bid, arguing that a Teva takeover would likely lead to job losses at Mylan and reduce access to cheap generic medicines in emerging markets. Continued...